No ischaemic events (n=1416) | Ischaemic events (n=104) | P value | |
Age (median, IQR) | 78 (17) | 76 (18) | 0.179 |
Sex (% women) | 706 (49.9) | 56 (53.8) | 0.477 |
Hypertension (%) | 1175/1415 (83.0) | 82 (78.8) | 0.282 |
Diabetes (%) | 474/1414 (33.5) | 36 (34.6) | 0.830 |
Hyperlipidamia (%) | 795/1415 (56.2) | 58 (55.8) | 1.000 |
Prior stroke or TIA (%) | 435/1415 (30.7) | 41 (39.4) | 0.079 |
Active smoking (%) | 170/1414 (12.0) | 13 (12.5) | 0.876 |
Congestive heart failure (%) | 346/1393 (24.8) | 25 (24.0) | 0.907 |
Coronary artery disease (%) | 440/1415 (31.1) | 36 (34.6) | 0.446 |
Peripheral vascular disease (%) | 93/1414 (6.6) | 7 (6.7) | 0.840 |
CHA2DS2-vasc score (median, IQR) | 5 (3) | 5 (3) | 0.215 |
AF type paroxysmal (%) | 687/1337 (51.4) | 49/94 (52.1) | 0.915 |
Home anticoagulation (%) | 502/1414 (35.5) | 44 (42.3) | 0.170 |
Systolic blood pressure (median, IQR) | 148 (34) | 152 (37) | 0.275 |
Diastolic blood pressure (median, IQR) | 80 (22) | 80 (21) | 0.929 |
NIHSS score (median, IQR) | 8 (12) | 8 (12) | 0.767 |
Glucose (median, IQR) | 121 (45) | 125 (41) | 0.609 |
LDL (median, IQR) | 77 (44) | 78 (33) | 0.951 |
Positive troponin (%) | 151/1094 (13.8) | 14/80 (17.5) | 0.403 |
Alteplase (%) | 412/1416 (29.1) | 25 (24.0) | 0.313 |
Thrombectomy (%) | 358/1416 (25.2) | 27 (25.9) | 0.907 |
Ischaemic stroke ≥10 mL (%) | 770/1308 (58.9) | 57/95 (60.0) | 0.914 |
Cardiac thrombus (%) | 18/1336 (1.3) | 1/95 (1.1) | 1.000 |
Moderate to severe mitral stenosis (%) | 23/1337 (1.7) | 3/95 (3.2) | 0.246 |
Severe left atrial enlargement (%) | 437/1154 (37.9) | 31/78 (39.7) | 0.810 |
Left atrial volume (median, IQR) | 75 (41) | 72 (47) | 0.971 |
Ipsilateral atherosclerosis 50% or more (%) | 221/1389 (15.9) | 24 (23.1) | 0.073 |
Ejection fraction (median, IQR) | 59 (15) | 60 (11) | 0.652 |
Anticoagulation initiated (%) | 1213/1412 (85.9) | 87 (83.7) | 0.562 |
Time to initiating anticoagulation (median, IQR) | 4 (8) | 3 (8) | 0.358 |
AF, atrial fibrillation; LDL, low-density lipoprotein.